{
    "data": [
        {
            "id": "4314595",
            "type": "article",
            "attributes": {
                "publishOn": "2019-12-30T15:37:45-05:00",
                "isLockedPro": false,
                "commentCount": 59,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "134% Upside To The Bristol Myers CVR",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "48311",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "250162",
                            "type": "sentiment"
                        },
                        {
                            "id": "250163",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4314595-134-percent-upside-to-bristol-myers-cvr"
            }
        },
        {
            "id": "4314209",
            "type": "article",
            "attributes": {
                "publishOn": "2019-12-30T07:30:00-05:00",
                "isLockedPro": false,
                "commentCount": 64,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Looking For Dividend Security In 2020",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "102107",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/4314209-looking-for-dividend-security-in-2020"
            }
        },
        {
            "id": "4313613",
            "type": "article",
            "attributes": {
                "publishOn": "2019-12-20T16:31:12-05:00",
                "isLockedPro": false,
                "commentCount": 28,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Squibb: 2020 Total Return Play With A 2.8% Dividend Yield",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24634",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "249058",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4313613-bristol-myers-squibb-2020-total-return-play-2_8-percent-dividend-yield"
            }
        },
        {
            "id": "4311775",
            "type": "article",
            "attributes": {
                "publishOn": "2019-12-11T00:12:37-05:00",
                "isLockedPro": false,
                "commentCount": 94,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers' Dividend Increase Changes Everything",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "44781",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "246706",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4311775-bristol-myers-dividend-increase-changes-everything"
            }
        },
        {
            "id": "4311141",
            "type": "article",
            "attributes": {
                "publishOn": "2019-12-06T15:35:33-05:00",
                "isLockedPro": false,
                "commentCount": 36,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Squibb Prescribed For The Newborn Portfolio",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105388",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "245535",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4311141-bristol-myers-squibb-prescribed-for-newborn-portfolio"
            }
        },
        {
            "id": "4310677",
            "type": "article",
            "attributes": {
                "publishOn": "2019-12-05T01:20:08-05:00",
                "isLockedPro": false,
                "commentCount": 25,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Numerous Readouts And Pipeline Updates Coming For Bristol-Myers Squibb; Timing Key To CVR Payout",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "78545",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "245220",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4310677-numerous-readouts-and-pipeline-updates-coming-for-bristol-myers-squibb-timing-key-to-cvr"
            }
        },
        {
            "id": "4309193",
            "type": "article",
            "attributes": {
                "publishOn": "2019-11-26T10:31:57-05:00",
                "isLockedPro": false,
                "commentCount": 16,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Sell Celgene, Buy Bristol-Myers: Counting Profits At Full Time - What To Do Now",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "41431",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "243178",
                            "type": "sentiment"
                        },
                        {
                            "id": "244334",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4309193-sell-celgene-buy-bristol-myers-counting-profits-full-time-what-to-now"
            }
        },
        {
            "id": "4307885",
            "type": "article",
            "attributes": {
                "publishOn": "2019-11-19T17:17:09-05:00",
                "isLockedPro": false,
                "commentCount": 86,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Celgene: Bargain Bin At Bristol-Myers Squibb Deal Closing",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "22148",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "239890",
                            "type": "sentiment"
                        },
                        {
                            "id": "239699",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4307885-celgene-bargain-bin-bristol-myers-squibb-deal-closing"
            }
        },
        {
            "id": "4302371",
            "type": "article",
            "attributes": {
                "publishOn": "2019-11-04T19:21:53-05:00",
                "isLockedPro": false,
                "commentCount": 36,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "The Celgene CVR Could Be Worth As Much As $6.48",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "48311",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "78807",
                            "type": "sentiment"
                        },
                        {
                            "id": "78808",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4302371-celgene-cvr-be-worth-much-6_48"
            }
        },
        {
            "id": "4300592",
            "type": "article",
            "attributes": {
                "publishOn": "2019-10-30T17:50:46-04:00",
                "isLockedPro": false,
                "commentCount": 41,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Sell Celgene, Buy Bristol-Myers: Counting The Profits At The Halfway Mark",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "41431",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "77703",
                            "type": "sentiment"
                        },
                        {
                            "id": "77704",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4300592-sell-celgene-buy-bristol-myers-counting-profits-halfway-mark"
            }
        },
        {
            "id": "4298554",
            "type": "article",
            "attributes": {
                "publishOn": "2019-10-24T09:47:17-04:00",
                "isLockedPro": false,
                "commentCount": 32,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers: Dividend Stock, Low Valuation, Boost From Celgene",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "21798",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "75982",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4298554-bristol-myers-dividend-stock-low-valuation-boost-from-celgene"
            }
        },
        {
            "id": "4296762",
            "type": "article",
            "attributes": {
                "publishOn": "2019-10-16T09:10:34-04:00",
                "isLockedPro": false,
                "commentCount": 130,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "3 Reasons Bristol-Myers Could Still Double From Here",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101900",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "74513",
                            "type": "sentiment"
                        },
                        {
                            "id": "74514",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4296762-3-reasons-bristol-myers-still-double-from"
            }
        },
        {
            "id": "4294793",
            "type": "article",
            "attributes": {
                "publishOn": "2019-10-03T10:12:28-04:00",
                "isLockedPro": false,
                "commentCount": 9,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Squibb On Roll With Opdivo Results",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24757",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "71544",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4294793-bristol-myers-squibb-on-roll-opdivo-results"
            }
        },
        {
            "id": "4292233",
            "type": "article",
            "attributes": {
                "publishOn": "2019-09-18T09:49:10-04:00",
                "isLockedPro": false,
                "commentCount": 12,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Healthy Dividends: Finding Refuge In Bristol-Myers Squibb",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104805",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "67717",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4292233-healthy-dividends-finding-refuge-in-bristol-myers-squibb"
            }
        },
        {
            "id": "4289952",
            "type": "article",
            "attributes": {
                "publishOn": "2019-09-05T15:09:54-04:00",
                "isLockedPro": false,
                "commentCount": 22,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Why I'm Big On The Celgene/Bristol-Myers Deal",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "48311",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "65174",
                            "type": "sentiment"
                        },
                        {
                            "id": "65175",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4289952-why-big-on-celgene-bristol-myers-deal"
            }
        },
        {
            "id": "4288279",
            "type": "article",
            "attributes": {
                "publishOn": "2019-08-27T17:33:21-04:00",
                "isLockedPro": false,
                "commentCount": 14,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Squibb: Great Deal On Celgene And Undervalued",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "102404",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "62898",
                            "type": "sentiment"
                        },
                        {
                            "id": "62899",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4288279-bristol-myers-squibb-great-deal-on-celgene-and-undervalued"
            }
        },
        {
            "id": "4286625",
            "type": "article",
            "attributes": {
                "publishOn": "2019-08-19T12:30:50-04:00",
                "isLockedPro": false,
                "commentCount": 45,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Squibb Is Undervalued",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "102764",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "61062",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4286625-bristol-myers-squibb-is-undervalued"
            }
        },
        {
            "id": "4281145",
            "type": "article",
            "attributes": {
                "publishOn": "2019-08-03T04:19:47-04:00",
                "isLockedPro": false,
                "commentCount": 115,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Looks Incredibly Cheap",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "44781",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "56937",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4281145-bristol-myers-looks-incredibly-cheap"
            }
        },
        {
            "id": "4276949",
            "type": "article",
            "attributes": {
                "publishOn": "2019-07-24T07:29:37-04:00",
                "isLockedPro": false,
                "commentCount": 64,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Buy Celgene, Sell Bristol-Myers Squibb Ahead Of Merger Closing",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "54792",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "54249",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4276949-buy-celgene-sell-bristol-myers-squibb-ahead-of-merger-closing"
            }
        },
        {
            "id": "4275706",
            "type": "article",
            "attributes": {
                "publishOn": "2019-07-18T10:21:43-04:00",
                "isLockedPro": false,
                "commentCount": 128,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Sell Celgene, Buy Bristol-Myers Ahead Of Proposed Merger",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "41431",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "52938",
                            "type": "sentiment"
                        },
                        {
                            "id": "53264",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4275706-sell-celgene-buy-bristol-myers-ahead-of-proposed-merger"
            }
        },
        {
            "id": "4273337",
            "type": "article",
            "attributes": {
                "publishOn": "2019-07-03T13:13:15-04:00",
                "isLockedPro": false,
                "commentCount": 39,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Squibb Is Cheap",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24443",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "49565",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4273337-bristol-myers-squibb-is-cheap"
            }
        },
        {
            "id": "4273141",
            "type": "article",
            "attributes": {
                "publishOn": "2019-07-02T11:16:05-04:00",
                "isLockedPro": false,
                "commentCount": 25,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers: Otezla Divestiture Highlights Compelling Opportunity",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101850",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "48957",
                            "type": "sentiment"
                        },
                        {
                            "id": "48958",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4273141-bristol-myers-otezla-divestiture-highlights-compelling-opportunity"
            }
        },
        {
            "id": "4271249",
            "type": "article",
            "attributes": {
                "publishOn": "2019-06-20T10:52:00-04:00",
                "isLockedPro": false,
                "commentCount": 70,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Squibb And Celgene - On The Path To A Valuable Combination",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "80516",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "46411",
                            "type": "sentiment"
                        },
                        {
                            "id": "46412",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4271249-bristol-myers-squibb-and-celgene-on-path-to-valuable-combination"
            }
        },
        {
            "id": "4268363",
            "type": "article",
            "attributes": {
                "publishOn": "2019-06-05T06:03:50-04:00",
                "isLockedPro": false,
                "commentCount": 25,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Squibb And AbbVie: Pharma Dividend Opportunities With Large Margins Of Safety",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105006",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "42907",
                            "type": "sentiment"
                        },
                        {
                            "id": "42908",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4268363-bristol-myers-squibb-and-abbvie-pharma-dividend-opportunities-large-margins-of-safety"
            }
        },
        {
            "id": "4265780",
            "type": "article",
            "attributes": {
                "publishOn": "2019-05-22T11:03:00-04:00",
                "isLockedPro": false,
                "commentCount": 42,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Squibb: Share Repurchases No Benefit To Shareholders",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "41431",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "39827",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4265780-bristol-myers-squibb-share-repurchases-no-benefit-to-shareholders"
            }
        },
        {
            "id": "4264634",
            "type": "article",
            "attributes": {
                "publishOn": "2019-05-16T12:36:41-04:00",
                "isLockedPro": false,
                "commentCount": 132,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "These 3 High-Yield Blue Chips Are Very Strong Buys",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101900",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "38306",
                            "type": "sentiment"
                        },
                        {
                            "id": "38307",
                            "type": "sentiment"
                        },
                        {
                            "id": "38308",
                            "type": "sentiment"
                        },
                        {
                            "id": "38309",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4264634-3-high-yield-blue-chips-are-strong-buys"
            }
        },
        {
            "id": "4260646",
            "type": "article",
            "attributes": {
                "publishOn": "2019-05-06T17:02:58-04:00",
                "isLockedPro": false,
                "commentCount": 16,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Squibb And BMS-986036 In NASH: An Update",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104202",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "36011",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4260646-bristol-myers-squibb-and-bmsminus-986036-in-nash-update"
            }
        },
        {
            "id": "4257232",
            "type": "article",
            "attributes": {
                "publishOn": "2019-04-26T15:14:43-04:00",
                "isLockedPro": false,
                "commentCount": 16,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Earnings Call Positive For Celgene Holders",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "48311",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "33717",
                            "type": "sentiment"
                        },
                        {
                            "id": "33775",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4257232-bristol-myers-earnings-call-positive-for-celgene-holders"
            }
        },
        {
            "id": "4254617",
            "type": "article",
            "attributes": {
                "publishOn": "2019-04-16T00:43:44-04:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Turning Point IPO: Targeting A Massive Market",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104426",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "30296",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4254617-turning-point-ipo-targeting-massive-market"
            }
        },
        {
            "id": "4253818",
            "type": "article",
            "attributes": {
                "publishOn": "2019-04-10T14:20:51-04:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "IPO Update: Turning Point Therapeutics Aims For $125 Million IPO",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101421",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "29920",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4253818-ipo-update-turning-point-therapeutics-aims-for-125-million-ipo"
            }
        },
        {
            "id": "4253407",
            "type": "article",
            "attributes": {
                "publishOn": "2019-04-08T17:28:18-04:00",
                "isLockedPro": false,
                "commentCount": 112,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "3 Reasons Bristol-Myers Could Become One Of The Best Investments Of The Next 5 Years",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101900",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "28778",
                            "type": "sentiment"
                        },
                        {
                            "id": "28779",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4253407-3-reasons-bristol-myers-become-one-of-best-investments-of-next-5-years"
            }
        },
        {
            "id": "4253327",
            "type": "article",
            "attributes": {
                "publishOn": "2019-04-08T12:22:23-04:00",
                "isLockedPro": false,
                "commentCount": 25,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Squibb As A Dividend Growth Investment",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105006",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "28828",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4253327-bristol-myers-squibb-dividend-growth-investment"
            }
        },
        {
            "id": "4252005",
            "type": "article",
            "attributes": {
                "publishOn": "2019-03-31T17:59:04-04:00",
                "isLockedPro": false,
                "commentCount": 100,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Thoughts On A Post-Merger Bristol-Myers Squibb: Scaling From Celgene To Buy BMS",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "43041",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "27223",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4252005-thoughts-on-post-merger-bristol-myers-squibb-scaling-from-celgene-to-buy-bms"
            }
        },
        {
            "id": "4251986",
            "type": "article",
            "attributes": {
                "publishOn": "2019-03-31T13:11:06-04:00",
                "isLockedPro": false,
                "commentCount": 46,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "ISS Blesses Bristol-Myers Celgene Tie-Up. Now What?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "48311",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "27023",
                            "type": "sentiment"
                        },
                        {
                            "id": "27024",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4251986-iss-blesses-bristol-myers-celgene-tie-up-now-what"
            }
        },
        {
            "id": "4251526",
            "type": "article",
            "attributes": {
                "publishOn": "2019-03-28T09:35:29-04:00",
                "isLockedPro": false,
                "commentCount": 71,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Options Bets Paint Dire Outlook For Celgene/Bristol Deal",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "71685",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "26475",
                            "type": "sentiment"
                        },
                        {
                            "id": "26476",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4251526-options-bets-paint-dire-outlook-for-celgene-bristol-deal"
            }
        },
        {
            "id": "4251329",
            "type": "article",
            "attributes": {
                "publishOn": "2019-03-27T12:47:18-04:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Turning Point Therapeutics Files For U.S. IPO",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101421",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "26453",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4251329-turning-point-therapeutics-files-for-u-s-ipo"
            }
        },
        {
            "id": "4250768",
            "type": "article",
            "attributes": {
                "publishOn": "2019-03-25T07:42:19-04:00",
                "isLockedPro": false,
                "commentCount": 30,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Celgene's Shareholders, Not Bristol-Myers Squibb's, Should Reject The Deal",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104227",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "25890",
                            "type": "sentiment"
                        },
                        {
                            "id": "25891",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4250768-celgenes-shareholders-not-bristol-myers-squibbs-should-reject-deal"
            }
        },
        {
            "id": "4250754",
            "type": "article",
            "attributes": {
                "publishOn": "2019-03-25T06:34:12-04:00",
                "isLockedPro": false,
                "commentCount": 38,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Celgene/Bristol-Myers Merger: The Arb Spread Continuum Offers Clues",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24018",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "25836",
                            "type": "sentiment"
                        },
                        {
                            "id": "25837",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4250754-celgene-bristol-myers-merger-arb-spread-continuum-offers-clues"
            }
        },
        {
            "id": "4250086",
            "type": "article",
            "attributes": {
                "publishOn": "2019-03-20T16:43:18-04:00",
                "isLockedPro": false,
                "commentCount": 35,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Celgene Presents An Attractive Short-Term Investment Opportunity In March 2019",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "102293",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "24829",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4250086-celgene-presents-attractive-short-term-investment-opportunity-in-march-2019"
            }
        },
        {
            "id": "4249414",
            "type": "article",
            "attributes": {
                "publishOn": "2019-03-18T09:55:00-04:00",
                "isLockedPro": false,
                "commentCount": 10,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Capturing The Celgene-Bristol-Myers Deal Spread Using ETFs",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20093",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "23868",
                            "type": "sentiment"
                        },
                        {
                            "id": "23869",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4249414-capturing-celgene-bristol-myers-deal-spread-using-etfs"
            }
        },
        {
            "id": "4249175",
            "type": "article",
            "attributes": {
                "publishOn": "2019-03-15T15:54:06-04:00",
                "isLockedPro": false,
                "commentCount": 102,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "For Bristol-Myers Squibb's Sake, Celgene Merger Should Be Voted Down",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "87856",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "23709",
                            "type": "sentiment"
                        },
                        {
                            "id": "23710",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4249175-for-bristol-myers-squibbs-sake-celgene-merger-should-be-voted-down"
            }
        },
        {
            "id": "4248494",
            "type": "article",
            "attributes": {
                "publishOn": "2019-03-13T14:40:12-04:00",
                "isLockedPro": false,
                "commentCount": 29,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Squibb: Caforio Makes A Strong Showing At The Barclays Healthcare Conference",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "48311",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "23483",
                            "type": "sentiment"
                        },
                        {
                            "id": "23484",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4248494-bristol-myers-squibb-caforio-makes-strong-showing-barclays-healthcare-conference"
            }
        },
        {
            "id": "4248410",
            "type": "article",
            "attributes": {
                "publishOn": "2019-03-13T12:12:46-04:00",
                "isLockedPro": false,
                "commentCount": 37,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Options Betting Suggests Bristol's Proposed Takeover Of Celgene Will Fail",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "71685",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "23504",
                            "type": "sentiment"
                        },
                        {
                            "id": "23505",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4248410-options-betting-suggests-bristols-proposed-takeover-of-celgene-will-fail"
            }
        },
        {
            "id": "4247344",
            "type": "article",
            "attributes": {
                "publishOn": "2019-03-08T12:02:40-05:00",
                "isLockedPro": false,
                "commentCount": 65,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "A Closer Look At The Shareholder Makeup Of Bristol-Myers Squibb",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "48311",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "22795",
                            "type": "sentiment"
                        },
                        {
                            "id": "22796",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4247344-closer-look-shareholder-makeup-of-bristol-myers-squibb"
            }
        },
        {
            "id": "4246517",
            "type": "article",
            "attributes": {
                "publishOn": "2019-03-05T19:04:45-05:00",
                "isLockedPro": false,
                "commentCount": 61,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "If The Celgene Deal Fails, Who Would Buy Bristol-Myers Squibb?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "43041",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "10164",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4246517-celgene-deal-fails-who-buy-bristol-myers-squibb"
            }
        },
        {
            "id": "4245712",
            "type": "article",
            "attributes": {
                "publishOn": "2019-03-01T12:20:01-05:00",
                "isLockedPro": false,
                "commentCount": 79,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers/Celgene Can Learn From The Failed Qualcomm/NXP Deal",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25218",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "9792",
                            "type": "sentiment"
                        },
                        {
                            "id": "9793",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4245712-bristol-myers-celgene-can-learn-from-failed-qualcomm-nxp-deal"
            }
        },
        {
            "id": "4245694",
            "type": "article",
            "attributes": {
                "publishOn": "2019-03-01T11:39:25-05:00",
                "isLockedPro": false,
                "commentCount": 45,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Why Wellington Is Unlikely To Kill The Celgene Bristol-Myers Deal",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "48311",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "9720",
                            "type": "sentiment"
                        },
                        {
                            "id": "9721",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4245694-why-wellington-is-unlikely-to-kill-celgene-bristol-myers-deal"
            }
        },
        {
            "id": "4245580",
            "type": "article",
            "attributes": {
                "publishOn": "2019-03-01T02:18:36-05:00",
                "isLockedPro": false,
                "commentCount": 54,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Celgene Complications",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20694",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4245580-celgene-complications"
            }
        },
        {
            "id": "4243375",
            "type": "article",
            "attributes": {
                "publishOn": "2019-02-22T13:32:58-05:00",
                "isLockedPro": false,
                "commentCount": 12,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Why Sanofi Won't Try To Buy Bristol-Myers",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "48311",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "9051",
                            "type": "sentiment"
                        },
                        {
                            "id": "9052",
                            "type": "sentiment"
                        },
                        {
                            "id": "9053",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4243375-why-sanofi-wont-try-to-buy-bristol-myers"
            }
        },
        {
            "id": "4239915",
            "type": "article",
            "attributes": {
                "publishOn": "2019-02-11T13:19:39-05:00",
                "isLockedPro": false,
                "commentCount": 62,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "A Special Situation Set Up By Bristol-Myers Squibb's Offer For Celgene",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "42661",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "7712",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4239915-special-situation-set-up-bristol-myers-squibbs-offer-for-celgene"
            }
        },
        {
            "id": "4238283",
            "type": "article",
            "attributes": {
                "publishOn": "2019-02-05T15:01:04-05:00",
                "isLockedPro": false,
                "commentCount": 40,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Celgene/Bristol-Myers: Analyzing The News Of Starboard's Stake",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105033",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "7116",
                            "type": "sentiment"
                        },
                        {
                            "id": "7117",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4238283-celgene-bristol-myers-analyzing-news-of-starboards-stake"
            }
        },
        {
            "id": "4236404",
            "type": "article",
            "attributes": {
                "publishOn": "2019-01-29T15:16:05-05:00",
                "isLockedPro": false,
                "commentCount": 31,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Celgene: Long The Deal Spread",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "105033",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "6403",
                            "type": "sentiment"
                        },
                        {
                            "id": "6404",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4236404-celgene-long-deal-spread"
            }
        },
        {
            "id": "4235924",
            "type": "article",
            "attributes": {
                "publishOn": "2019-01-28T07:16:08-05:00",
                "isLockedPro": false,
                "commentCount": 14,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers - Appealing, With Or Without Celgene",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25120",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "6139",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4235924-bristol-myers-appealing-without-celgene"
            }
        },
        {
            "id": "4234281",
            "type": "article",
            "attributes": {
                "publishOn": "2019-01-18T13:05:36-05:00",
                "isLockedPro": false,
                "commentCount": 6,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "The Bristol-Myers Celgene Deal, And Other Ideas",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104650",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4234281-bristol-myers-celgene-deal-and-ideas"
            }
        },
        {
            "id": "4233520",
            "type": "article",
            "attributes": {
                "publishOn": "2019-01-15T14:45:53-05:00",
                "isLockedPro": false,
                "commentCount": 60,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "3 Reasons Bristol-Myers' $90 Billion Mega-Merger Makes It A Must Own Stock",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101900",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "4871",
                            "type": "sentiment"
                        },
                        {
                            "id": "4872",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4233520-3-reasons-bristol-myers-90-billion-mega-merger-makes-must-own-stock"
            }
        },
        {
            "id": "4233527",
            "type": "article",
            "attributes": {
                "publishOn": "2019-01-15T14:28:21-05:00",
                "isLockedPro": false,
                "commentCount": 15,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Squibb Stock Issued For Celgene: I Plan To Keep It",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24757",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "4810",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4233527-bristol-myers-squibb-stock-issued-for-celgene-i-plan-to-keep"
            }
        },
        {
            "id": "4233282",
            "type": "article",
            "attributes": {
                "publishOn": "2019-01-14T14:14:38-05:00",
                "isLockedPro": false,
                "commentCount": 16,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Eli Lilly, Loxo Make More Sense Than Bristol Myers, Celgene",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103071",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "4775",
                            "type": "sentiment"
                        },
                        {
                            "id": "4776",
                            "type": "sentiment"
                        },
                        {
                            "id": "4777",
                            "type": "sentiment"
                        },
                        {
                            "id": "4778",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4233282-eli-lilly-loxo-make-sense-bristol-myers-celgene"
            }
        },
        {
            "id": "4233048",
            "type": "article",
            "attributes": {
                "publishOn": "2019-01-13T15:49:28-05:00",
                "isLockedPro": false,
                "commentCount": 21,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers: Fattening Up The Pipeline With Celgene",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101850",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "4432",
                            "type": "sentiment"
                        },
                        {
                            "id": "4433",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4233048-bristol-myers-fattening-up-pipeline-celgene"
            }
        },
        {
            "id": "4232783",
            "type": "article",
            "attributes": {
                "publishOn": "2019-01-11T07:10:48-05:00",
                "isLockedPro": false,
                "commentCount": 137,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Buying Celgene",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "43041",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "4482",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4232783-buying-celgene"
            }
        },
        {
            "id": "4231701",
            "type": "article",
            "attributes": {
                "publishOn": "2019-01-07T01:10:15-05:00",
                "isLockedPro": false,
                "commentCount": 17,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "What The Celgene Deal Means For The Biotech Sector",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "103558",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "3893",
                            "type": "sentiment"
                        },
                        {
                            "id": "3894",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4231701-what-celgene-deal-means-for-biotech-sector"
            }
        },
        {
            "id": "4231667",
            "type": "article",
            "attributes": {
                "publishOn": "2019-01-06T16:46:52-05:00",
                "isLockedPro": false,
                "commentCount": 25,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Can Bristol-Myers Squibb's Balance Sheet Handle The Celgene Acquisition?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104097",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "3770",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4231667-can-bristol-myers-squibbs-balance-sheet-handle-celgene-acquisition"
            }
        },
        {
            "id": "4231664",
            "type": "article",
            "attributes": {
                "publishOn": "2019-01-06T16:33:51-05:00",
                "isLockedPro": false,
                "commentCount": 36,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Squibb Acquisition Of Celgene Is Brilliant",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "80516",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "3760",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4231664-bristol-myers-squibb-acquisition-of-celgene-is-brilliant"
            }
        },
        {
            "id": "4231533",
            "type": "article",
            "attributes": {
                "publishOn": "2019-01-04T16:16:47-05:00",
                "isLockedPro": false,
                "commentCount": 64,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Buys Celgene: Smart Plan Or A Rush To Action?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "58061",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "3732",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4231533-bristol-myers-buys-celgene-smart-plan-rush-to-action"
            }
        },
        {
            "id": "4231438",
            "type": "article",
            "attributes": {
                "publishOn": "2019-01-04T08:51:34-05:00",
                "isLockedPro": false,
                "commentCount": 87,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "What Should Celgene Shareholders Do In Light Of The Bristol-Myers Squibb Deal?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "38311",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "3719",
                            "type": "sentiment"
                        },
                        {
                            "id": "3720",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4231438-what-should-celgene-shareholders-in-light-of-bristol-myers-squibb-deal"
            }
        },
        {
            "id": "4231391",
            "type": "article",
            "attributes": {
                "publishOn": "2019-01-03T22:34:52-05:00",
                "isLockedPro": false,
                "commentCount": 92,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers: Analysis On Celgene Deal",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25120",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "3721",
                            "type": "sentiment"
                        },
                        {
                            "id": "3722",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4231391-bristol-myers-analysis-on-celgene-deal"
            }
        },
        {
            "id": "4231341",
            "type": "article",
            "attributes": {
                "publishOn": "2019-01-03T16:09:03-05:00",
                "isLockedPro": false,
                "commentCount": 112,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Squibb's Bid To Swallow Celgene Is A Bane For An Overcrowded Oncology Space",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101961",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "3700",
                            "type": "sentiment"
                        },
                        {
                            "id": "3701",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4231341-bristol-myers-squibbs-bid-to-swallow-celgene-is-bane-for-overcrowded-oncology-space"
            }
        },
        {
            "id": "4231252",
            "type": "article",
            "attributes": {
                "publishOn": "2019-01-03T11:12:07-05:00",
                "isLockedPro": false,
                "commentCount": 85,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bristol-Myers Squibb And Celgene",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20694",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1199",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4231252-bristol-myers-squibb-and-celgene"
            }
        }
    ]
}